Literature DB >> 12810796

Apolipoprotein E genotypes and clinical outcome in Guillain-Barré syndrome.

J Pritchard1, R A C Hughes, J H Rees, H J Willison, J A R Nicoll.   

Abstract

BACKGROUND: Polymorphism of the gene encoding the cholesterol transport protein apolipoprotein E (APOE, gene; apoE, protein), known to be involved in axonal regeneration and remyelination, influences outcome after a variety of central nervous system disorders. Apolipoprotein E gene polymorphisms could affect recovery from Guillain-Barré syndrome.
OBJECTIVE: To correlate APOE genotypes with residual disability and degree of improvement in Guillain-Barré syndrome, assessed one year after presentation
METHODS: 91 patients with the syndrome were recruited from southeast England and their APOE genotypes were determined.
RESULTS: There were no clear differences in APOE genotype or allele frequencies when comparing the 91 patients with controls, nor when comparing 81 patients with good outcome and 10 with poor outcome.
CONCLUSIONS: APOE genotype did not influence susceptibility to Guillain-Barré syndrome or recovery from it. This may be because our sample size of 91 was not sufficiently large to detect small differences in recovery associated with different APOE genotypes, or because cholesterol transportation is not a crucial rate limiting step in peripheral nerve regeneration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810796      PMCID: PMC1738571          DOI: 10.1136/jnnp.74.7.971

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  2 in total

Review 1.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

Review 2.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.